INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss

INmune Bio (NASDAQ: INMB) reported no revenue for Q2 2026, unchanged from a year earlier, while basic and diluted loss per share narrowed to $0.05 from $1.05. Net loss fell to approximately $1.3 million from $24.5 million, largely because R&D became a benefit following recognition of an additional Australian tax rebate and the prior-year quarter included a $16.5 million impairment. The company ended June with $18.4 million in cash while advancing Ebstrocel toward regulatory filings and XPro toward a registrational Alzheimer’s disease study.

Core earnings data

The sharp reduction in INmune Bio’s quarterly loss was not driven by revenue, which remained at zero. Instead, R&D shifted from a $5.8 million expense to a $0.8 million benefit, while the year-earlier period included a $16.5 million impairment of acquired in-process R&D assets.

Together, the $6.6 million year-over-year swing in R&D and the absence of the impairment account for almost all of the approximately $23.2 million reduction in net loss. General and administrative expense was essentially unchanged at approximately $2.3 million.

The R&D benefit makes the quarter’s expense base less representative of development activity than a conventional positive R&D expense would be. With no quarterly revenue, continued financial performance remains closely tied to development spending, tax credits and access to funding.

Business and platform progress

Ebstrocel moves closer to regulatory filings

INmune Bio reported formal alignment with the UK Medicines and Healthcare products Regulatory Agency across the chemistry, manufacturing and controls, non-clinical and clinical components of its planned Ebstrocel Marketing Authorization Application for recessive dystrophic epidermolysis bullosa. The MHRA also approved the Pediatric Investigation Plan in less than three months, preserving the company’s planned 2026 UK filing timetable.

On manufacturing, the company processed its first commercial-ready umbilical cord tissues at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in the UK. The transferred process is designed to support confirmatory development, regulatory submissions and potential commercial supply, although Ebstrocel has not received regulatory approval.

Preparations for the open-label Phase 3 confirmatory study continued, with first patient treatment planned for Q4 2026. INmune Bio also expanded its agreement with Anthony Nolan Cord Blood Bank to secure long-term access to umbilical cord tissue.

XPro gains Fast Track status and reports MRI findings

In the Phase 2 MINDFuL trial, XPro produced a statistically significant treatment effect on a white-matter myelin MRI biomarker in the full modified intent-to-treat population, with a p-value of 0.0028 and Cohen’s d of 0.46 across 200 patients. The effect was larger in the 100-patient biomarker-enriched population, where the p-value was 0.0098 and Cohen’s d was 0.59.

The published results also showed directionally consistent effects across several endpoints in the protocol-defined Alzheimer’s disease with inflammation subgroup. No ARIA-E or ARIA-H events were observed during the 24-week study.

The FDA granted XPro, also known as pegipanermin, Fast Track designation for early Alzheimer’s disease. This allows more frequent interaction with the agency and potential eligibility for expedited review mechanisms, but it does not constitute approval or establish that the planned registrational trial will succeed.

Cash flow and balance sheet

INmune Bio used $6.6 million of cash in operations during the first six months of 2026, down from $14.2 million in the comparable 2025 period. These are six-month figures rather than standalone Q2 cash flows.

Cash decreased by $6.3 million from the end of 2025 to June 30, reflecting operating and investing outflows that exceeded the limited cash raised through financing activities.

The company received an approximately $4.2 million Australian R&D tax rebate in July 2026. Because the receipt occurred after quarter-end, it was not included in the June 30 cash balance.

Development and regulatory milestones

The next stated milestones center on Ebstrocel regulatory submissions and the design of XPro’s registrational program. Meeting these dates would move both platforms forward, but the planned submissions do not assure acceptance or approval.

Recent insider transactions

The supplied six-month summary records no insider purchases or sales and approximately 2.98 million total insider shares held. Separately, six transactions were reported for the latest two-year period, including three derivative-security conversions on July 2, 2026; the source did not specify the unit for the reported values.

The reported roles reflect the information attached to each transaction. Derivative conversions should not be treated as equivalent to open-market purchases or interpreted on their own as a statement about the company’s prospects.

Risks investors need to watch

• Funding requirements: INmune Bio had $18.4 million in cash at quarter-end and used $6.6 million in operations during the first half. The company states that substantial additional funding may be required to continue development, clinical studies and potential commercialization.
• Regulatory timing and approval: Ebstrocel still requires successful submissions and regulatory review in the UK, EU and United States. The planned filing dates may change, and no approval is assured.
• Manufacturing and Phase 3 execution: The commercial-ready manufacturing milestone reduces one operational hurdle, but the company must still demonstrate manufacturing consistency, supply sufficient product and execute the planned confirmatory trial.
• XPro clinical validation: The Phase 2 MRI findings and Fast Track designation support further development, but the registrational Phase 2b/3 protocol has not yet been submitted. The biomarker results must still translate into evidence sufficient for regulatory approval.
• Expense comparability: The quarterly loss improvement depended heavily on an R&D tax-credit benefit and the absence of a prior-year impairment, rather than revenue growth. Future reported expenses may therefore differ materially from Q2’s unusually low level.

Summary

INmune Bio’s Q2 2026 net loss narrowed substantially, but the improvement primarily reflected tax-credit accounting and the absence of a prior-year impairment while revenue remained at zero. Operationally, the company advanced Ebstrocel’s manufacturing and UK regulatory preparations and added FDA Fast Track status to XPro’s Phase 2 MRI findings. The main issues to monitor are execution against upcoming filing and trial timelines, the durability of clinical evidence and the cash required to fund both late-stage programs.